| Name | Title | Contact Details |
|---|---|---|
Pascal Wotling |
Chief Technical Operations Officer | Profile |
Pareto Biotechnologies has pioneered development of a revolutionary synthetic biology platform that produces naturally derived, high value “designer molecules.” Pareto’s technology is the result of over a decade of academic and private sector research and intellectual property focused on one particular polyketide pathway. Building on Dr. Joe Noel’s groundbreaking research at the Salk Institute, this pathway – previously dismissed as the “poor man’s pathway” – is the foundation of Pareto’s platform, capable of generating known products and novel molecules. In the near term, Pareto will introduce “designer molecules” as cosmetics, flavors and fragrances including molecules with properties unlike anything previously experienced. In the long term, Pareto’s molecules will be designed to enhance nutraceuticals, pharmaceuticals, and industrial commodities. Pareto’s potential is limitless. Join us as we ignite a molecular revolution
3DBio is the first company implanting personalized 3D-printed living tissues in patients. #3DBioPrinting #3DBio
Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics.
EndGenitor Technologies is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Osage Bio Energy is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.